Leerink upgraded Progyny (PGNY) to Outperform from Market Perform with an unchanged price target of $28, calling Progyny’s second positive pre-announcement in six months “yet another signal that membership activity has rebounded from last year’s lows.” While the firm had previously been “cautiously optimistic” that Q1 results were the start of a trend but, today’s data “gives us a bit more comfort” in becoming more constructive, the analyst tells investors.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PGNY:
- Progyny upgraded to Outperform from Market Perform at Leerink
- Progyny Secures $200M Credit Facility with JPMorgan
- Progyny enters revolving credit facility for up to $200M
- Progyny sees Q2 results ‘slightly better than’ guidance ranges on Q1 call
- Hinge Health, Progyny partnership ‘mutually beneficial,’ says Morgan Stanley